Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2001

View Archived Issues

Phase III trials of Thymitaq to begin in Canada

NeoTherapeutics begins pivotal trial of Neotrofin in Alzheimer's disease

SciClone's Zadaxin receives approval for hepatitis B in India

TCV-309 improves organ dysfunction and morbidity, but not mortality, in septic shock

Pravastatin therapy associated with significant risk reduction for diabetes

Fujisawa begins marketing Seroquel in Japan

New AZT prodrug with increased in vitro anti-HIV activity

Amrad and GlaxoSmithKline enter alliance for development of cancer and infectious disease therapies

FDA extends approval of Toprol-XL to include heart failure

In vivo pharmacological profile of SDZ-249-665, a capsaicin analogue for inflammatory pain

Schering-Plough seeks FDA approval for PEG-Intron/Rebetol combination

High-dose Rebif recommended for early first-line treatment of relapsing-remitting MS

Significant advance in pediatric medicine approved for use in Europe

BioStratum grants Pyridorin rights to Kowa for Japan and other Asian countries

DHA-clozapine appears to have enhanced efficacy and safety compared to clozapine

Promising preliminary clinical results reported for Cell Therapeutics' PG-TXL

Results with INGN-201 indicate new strategy for cancer immunotherapy

YM BioSciences extends EGF cancer vaccine trial to include U.K. sites

Combinations of etanercept and a COX-2 inhibitor claimed by Pharmacia for Rx of inflammation

Preparation and use of new brain GABA receptor ligands

New compounds from Toyama as remedies for neurodegenerative disorders

Chemokine CCR5 receptor antagonists useful for HIV infection

Drugs particularly useful in ulcer treatment or prevention patented jointly by Sankyo and Ube

Novel heterocyclic PKC inhibitors claimed for improving complications of diabetes

Japanese labs design new series of ribonucleotide reductase inhibitors

Rhodanine derivatives inhibit amyloid protein aggregation, image amyloid deposits

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...